Visibility Is Now Velocity:
Gross–to–Net in Pharma’s New Era
The paths forward for Manufacturers in 2026 and beyond
See GTN Risk Before It Hits Your Earnings
Finance teams are losing visibility at the worst possible moment.
As policy shifts, payer dynamics, and regulatory scrutiny accelerate, traditional GTN models are breaking down; leaving teams reliant on spreadsheets and late-cycle analysis to react after financial impact is already locked in.
In this paper, you’ll learn:
- Why GTN risk is accelerating across pharma
- Where legacy models fall short in today’s environment
- How AI can improve early insight and scenario modeling
- What leading CFOs are doing to regain control
The shift is clear: from explaining results to controlling outcomes. GTN success is no longer about accuracy alone, but about early visibility, explainability, and the ability to act before financial outcomes are set.
Get the insights finance leaders are using now. Download your copy.
Download the Research
Brought to you by Argano...
A leading digital services consultancy serving the pharmaceutical and medical device industries, Argano is uniquely positioned to solve your challenges—no matter the complexity, location, or technology—delivering operational excellence and transformative results.
We’re delighted to offer this guidance and are standing by to help your company make bold strides in 2026 and beyond. Learn more about our GTN solutions and services here or contact us for a free consultation.
